公开(公告)号：US07244411B2

公开(公告)日：2007-07-17

申请号：US10988943

申请日：2004-11-15

申请人： Lázaro Hiram Betancourt Núñez ,  Jorge Fernández de Cossio Dorta-Duque ,  Vladimir Armando Besada Pérez ,  Jeovanis Gil Valdés ,  Luis Javier González López ,  Gabriel Ramón Padrón Palomares ,  Rolando Pajón Feyt ,  Félix Modesto Álvarez Gil

发明人： Lázaro Hiram Betancourt Núñez ,  Jorge Fernández de Cossio Dorta-Duque ,  Vladimir Armando Besada Pérez ,  Jeovanis Gil Valdés ,  Luis Javier González López ,  Gabriel Ramón Padrón Palomares ,  Rolando Pajón Feyt ,  Félix Modesto Álvarez Gil

IPC分类号： A61K51/00 ,  A61M36/14

CPC分类号： G01N33/6848 ,  C12Q1/37

摘要： The present invention describes a method of selective peptide isolation for the identification and quantitative analysis of proteins in complex mixture. The method comprises the selective isolation from every protein of those peptides that neither contain arginine nor histidine (NHNR peptides), and the determination of the relative concentrations of one or several proteins in different samples from the ratio between the areas of the estimated theoretical spectra for the NHNR peptides labeled with different isotopes in each sample. The determination of the relative concentration of proteins is valid for any type of isotopic label of the NHNR peptides. The method avoids the separation and purification of the proteins present in a complex mixture, and the analysis of all peptides generated from the enzymatic digest of the samples. The method is applicable to the identification of proteins with vacunal, therapeutic and diagnostic aims.

摘要翻译： 本发明描述了用于鉴定和定量分析复合物中蛋白质的选择性肽分离方法。 该方法包括从不含精氨酸和组氨酸（NHNR肽）的那些肽的每种蛋白质的选择性分离，以及将不同样品中一种或几种蛋白质的相对浓度与估计的理论光谱面积之比 在每个样品中用不同同位素标记的NHNR肽。 蛋白质的相对浓度的测定对于NHNR肽的任何类型的同位素标记是有效的。 该方法避免了复杂混合物中存在的蛋白质的分离和纯化，以及从样品的酶促消化产生的所有肽的分析。 该方法适用于鉴定具有病毒，治疗和诊断目的的蛋白质。

公开(公告)号：US5637491A

公开(公告)日：1997-06-10

申请号：US354618

申请日：1994-12-13

申请人： Hernan R. Campana ,  Bianca M. Garcia Garcia ,  Julio M. Delgado Boada ,  Jose A. Cremata Alvarez ,  Maria E. Gonzalez Martinez ,  Emilio M. Clark ,  Dania M. Curbelo ,  Luis S. Herrera Martinez ,  Manuel R. Raices Perez-Castaneda ,  Efrain R. Jiminez ,  Rossana G. Fernandez ,  Vivian M. Cordova ,  Carlos F. Patron

发明人： Hernan R. Campana ,  Bianca M. Garcia Garcia ,  Julio M. Delgado Boada ,  Jose A. Cremata Alvarez ,  Maria E. Gonzalez Martinez ,  Emilio M. Clark ,  Dania M. Curbelo ,  Luis S. Herrera Martinez ,  Manuel R. Raices Perez-Castaneda ,  Efrain R. Jiminez ,  Rossana G. Fernandez ,  Vivian M. Cordova ,  Carlos F. Patron

IPC分类号： C12N9/46 ,  C12N15/55 ,  C12N9/44

CPC分类号： C12N9/2454

摘要： A method for the isolation and expression of a gene coding for dextranase of the fungus Penicillium minioluteum. This enzyme of fungal origin is produced by expression at high levels in yeast. For this purpose, a cDNA copy of the mRNA coding for dextranase enzyme of the Penicillium minioluteum fungus was isolated and sequenced. This cDNA was transfered into Pichia pastoris cells. Recombinant yeasts capable of secreting dextranase to the culture medium were obtained thereby. The dextranase enzyme obtained can be used, e.g. in the sugar industry to hydrolyze the dextran in cane juices to increase the sugar production.

摘要翻译： 分离和表达编码真菌青霉的葡聚糖酶的基因的方法。 这种真菌来源的酶是通过在酵母中高水平表达来产生的。 为此目的，分离编码微小霉菌的葡聚糖酶的mRNA的cDNA拷贝并测序。 将该cDNA转入毕赤酵母细胞。 由此获得能够将葡聚糖酶分泌到培养基中的重组酵母。 获得的葡聚糖酶可以使用，例如 在糖业中水解甘蔗汁中的葡聚糖以增加糖的产量。

公开(公告)号：US09603900B2

公开(公告)日：2017-03-28

申请号：US14839114

申请日：2015-08-28

申请人： Centro de Ingenieria Genetica y Biotecnologia

发明人： Mario Pablo Estrada Garcia ,  Juana Maria Lugo Gonzalez ,  Yamila Carpio Gonzalez ,  Carolina Tafalla Pineiro

IPC分类号： A61K9/08 ,  A61K38/22 ,  A61K31/7056 ,  A61K9/00 ,  A61K9/51

CPC分类号： A61K38/2278 ,  A61K9/0019 ,  A61K9/0056 ,  A61K9/08 ,  A61K9/5153 ,  A61K31/7056 ,  A61K38/22 ,  A61K2300/00

摘要： The present invention relates to the use of pituitary adenylate cyclase activating polypeptide (PACAP) in the treatment of viral diseases and infectious diseases caused by viruses in aquatic organisms. PACAP, alone or combined with an antiviral molecule, demonstrated its effectiveness by increasing the survival of fish or crustaceans infected by viruses when it was administered orally, by injection or by immersion baths. Furthermore, it was observed that treated organisms keep or increase its weight as compared to infected and non-treated organisms. PACAP or PACAP-containing combinations decreased the viral load in tissues and organs susceptible to viral infections as it was determined by RT-PCR.

公开(公告)号：US09278118B2

公开(公告)日：2016-03-08

申请号：US14518242

申请日：2014-10-20

申请人： Centro de Ingenieria Genetica Y Biotecnologia ,  BIOREC S.A.

发明人： Silvio Ernesto Perea Rodriguez ,  Yasser Perera Negrin ,  Arielis Rodríguez Ulloa ,  Jeovanis Gil Valdés ,  Yassel Ramos Gómez ,  Lila Rosa Castellanos Serra ,  Lázaro Hiram Betancourt Núñez ,  Aniel Sánchez Puente ,  Jorge Fernández de Cossio Dorta Duque ,  Boris Ernesto Acevedo Castro ,  Luis Javier González López ,  Vladimir Besada Pérez ,  Daniel Fernando Alonso ,  Daniel Eduardo Gomez

IPC分类号： A61K38/04 ,  C07K7/04 ,  A61K38/08 ,  A61K31/7048 ,  A61K31/282 ,  A61K31/7068 ,  A61K31/7076 ,  A61K31/136

CPC分类号： A61K38/08 ,  A61K31/136 ,  A61K31/282 ,  A61K31/337 ,  A61K31/407 ,  A61K31/475 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/555 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K31/7076 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

摘要： This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

摘要翻译： 本发明涉及含有酪蛋白激酶2（CK2）肽抑制剂（称为P15）以及癌症治疗中使用的标准化学治疗药物并且分开或依次给药的药物组合。 化疗药物包括顺铂，紫杉醇，长春花生物碱，5-氟尿嘧啶，多柔比星，环磷酰胺，依托泊苷，丝裂霉素C，伊马替尼，iressa，velcade（硼替佐米），阿糖胞苷（Ara C），氟达拉滨和米托蒽醌。 P15肽与抗癌药物之间的协同作用实现了组合中每种细胞抑制药物的有效浓缩，其比单独的每种细胞抑制药物低10至100倍。 本发明中描述的药物组合物与抗癌治疗剂报道的药物组合物相比表现出较低的毒性，因此它代表其用于癌症治疗的关键优势。 此外，通过用P15肽进行预处理，该药物组合的连续施用导致难治性肿瘤对抗癌治疗剂的化学敏感性。

公开(公告)号：US09226946B2

公开(公告)日：2016-01-05

申请号：US14490856

申请日：2014-09-19

申请人： Centro de Ingenieria Genetica Y Biotecnologia

发明人： Silvio Ernesto Perea Rodríguez ,  Yasser Perera Negrín ,  Arielis Rodríguez Ulloa ,  Jeovanis Gil Valdés ,  Yassel Ramos Gómez ,  Lila Rosa Castellanos Serra ,  Lázaro Hiram Betancourt Núñez ,  Aniel Sánchez Puente ,  Jorge Fernández de Cossio Dorta Duque ,  Boris Ernesto Acevedo Castro ,  Luis Javier González López ,  Vladimir Besada Pérez ,  Daniel Fernando Alonso ,  Daniel Eduardo Gomez

IPC分类号： A61K38/04 ,  C07K7/00 ,  A61K38/08 ,  A61K31/555 ,  A61K33/24 ,  A61K45/06 ,  A61K31/337 ,  A61K31/407 ,  A61K31/475 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704

CPC分类号： A61K38/08 ,  A61K31/136 ,  A61K31/282 ,  A61K31/337 ,  A61K31/407 ,  A61K31/475 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/555 ,  A61K31/675 ,  A61K31/69 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K31/7076 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

摘要： This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

摘要翻译： 本发明涉及含有酪蛋白激酶2（CK2）肽抑制剂（称为P15）以及癌症治疗中使用的标准化学治疗药物并且分开或依次给药的药物组合。 化疗药物包括顺铂，紫杉醇，长春花生物碱，5-氟尿嘧啶，多柔比星，环磷酰胺，依托泊苷，丝裂霉素C，伊马替尼，iressa和velcade（硼替佐米）。 P15肽与抗癌药物之间的协同作用实现了组合中每种细胞抑制药物的有效浓缩，其比单独的每种细胞抑制药物低10至100倍。 本发明中描述的药物组合物与抗癌治疗剂报道的药物组合物相比表现出较低的毒性，因此它代表其用于癌症治疗的关键优势。 此外，通过用P15肽进行预处理，该药物组合的连续施用导致难治性肿瘤对抗癌治疗剂的化学敏感性。

公开(公告)号：US09034339B2

公开(公告)日：2015-05-19

申请号：US13859314

申请日：2013-04-09

申请人： Centro De Ingenieria Genetica Y Biotecnologia

发明人： Yamila Carpio Gonzalez ,  Mario Pablo Estrada Garcia

IPC分类号： A61K39/395 ,  A61K39/00 ,  A61K39/38 ,  C07K1/00 ,  C07K14/00 ,  C07K17/00 ,  C07H21/02 ,  C07K14/435 ,  A61K38/00

CPC分类号： A61K39/0003 ,  A23K50/80 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/552 ,  C07K14/43509 ,  C07K2319/00

摘要： The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a vaccine formulation as a purified protein and/or naked DNA, to induce an immune response in aquatic organisms against different ectoparasite species, including the known as sea lice, and pathogens associated with these infestations. The vaccine preparations, administered by oral route, immersion bath or injection, demonstrated its efficacy by producing IgM humoral immune response and reducing the number of parasites per fish in the vaccinated fishes.

摘要翻译： 本发明涉及新基因的分离和克隆，通过使用重组系统产生由该基因编码的蛋白质，以及将该抗原在疫苗制剂中用作纯化的蛋白质和/或裸DNA， 在水生生物中诱导针对不同外寄生物种的免疫应答，包括已知的海虱和与这些侵染有关的病原体。 通过口服途径，浸浴或注射给药的疫苗制剂通过产生IgM体液免疫应答并减少接种的鱼类中每条鱼的寄生虫数量来证明其功效。

公开(公告)号：US08833306B2

公开(公告)日：2014-09-16

申请号：US12094339

申请日：2006-11-20

申请人： Juana Maria Lugo González ,  Mario Pablo Estrada Garcia ,  Alina Rodriguez Mallon ,  Yamila Carpio González ,  Antonio Morales Rojas ,  Osmany Rodrigo González De Sosa ,  Reynold Morales Fernández ,  Fidel Francisco Herrera Miyares

发明人： Juana Maria Lugo González ,  Mario Pablo Estrada Garcia ,  Alina Rodriguez Mallon ,  Yamila Carpio González ,  Antonio Morales Rojas ,  Osmany Rodrigo González De Sosa ,  Reynold Morales Fernández ,  Fidel Francisco Herrera Miyares

IPC分类号： A61K38/18 ,  A01K61/00 ,  A01K61/02

CPC分类号： A61K38/17 ,  A01K61/80 ,  A23K20/147 ,  A23K50/80 ,  C07K14/57563 ,  Y02A40/845

摘要： The present invention is related to the use of variants of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) to stimulate the growth and to improve the immunological system of aquatic organisms. The variants of the peptide were provided by immersion, injection or as a food additive.

摘要翻译： 本发明涉及使用垂体腺苷酸环化酶活化多肽（PACAP）的变体来刺激生长并改善水生生物的免疫系统。 通过浸渍，注射或作为食品添加剂提供肽的变体。

公开(公告)号：US08729226B2

公开(公告)日：2014-05-20

申请号：US13700286

申请日：2011-05-31

申请人： Maribel Guerra Vallespi ,  Julio Raúl Fernández Massó ,  Alexis Musacchio Lasa ,  Jeovanis Gil Valdés ,  Osvaldo Reyes Acosta ,  Brizaida Maylin Oliva Argüelles

发明人： Maribel Guerra Vallespi ,  Julio Raúl Fernández Massó ,  Alexis Musacchio Lasa ,  Jeovanis Gil Valdés ,  Osvaldo Reyes Acosta ,  Brizaida Maylin Oliva Argüelles

IPC分类号： A61K38/00

CPC分类号： C12N15/11 ,  A61K31/505 ,  A61K31/513 ,  A61K33/24 ,  A61K38/10 ,  A61K38/1767 ,  A61K45/06 ,  A61K48/00 ,  C07K7/08 ,  G01N33/574 ,  A61K2300/00

摘要： This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.

摘要翻译： 本发明描述了通过增加与降低或阻断癌细胞增殖相关的COMMD1蛋白的核定位来治疗癌症的方法。 本发明还涉及在制造用于癌症治疗的药物中增加COMMD1蛋白的核定位的试剂的用途。 这些试剂可以是其他化合物中的肽或蛋白质。 本发明还涉及来自序列HARIKPTFRRLKWKKYKGKFW的肽的优化，以增加蛋白质COMMD的核定位，从而提高该肽的抗肿瘤效果。

公开(公告)号：US08674063B2

公开(公告)日：2014-03-18

申请号：US12513085

申请日：2007-10-30

申请人： Glay Chinea Santiago ,  Vivian Huerta Galindo ,  Alejandro Miguel Martin Dunn ,  Noralvis Fleitas Salazar ,  Osmany Guirola Cruz ,  Patricia Gabriela Toledo Mayora ,  Mónica Sarría Núñez ,  Alexis Musacchio Lasa ,  Olvaldo Reyes Acosta ,  Hilda Elisa Garay Pérez ,  Anìa Cabrales Rico

发明人： Glay Chinea Santiago ,  Vivian Huerta Galindo ,  Alejandro Miguel Martin Dunn ,  Noralvis Fleitas Salazar ,  Osmany Guirola Cruz ,  Patricia Gabriela Toledo Mayora ,  Mónica Sarría Núñez ,  Alexis Musacchio Lasa ,  Olvaldo Reyes Acosta ,  Hilda Elisa Garay Pérez ,  Anìa Cabrales Rico

IPC分类号： C07K14/00

CPC分类号： A61K47/48315 ,  A61K38/00 ,  A61K47/645 ,  C07K14/005 ,  C07K2319/04 ,  C07K2319/10 ,  C12N2770/24022 ,  C12N2770/24122 ,  C12N2770/24222 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393 ,  Y02A50/395

摘要： The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family.

摘要翻译： 本发明是相对于嵌合肽，其主要结构保持至少一个片段，其抑制来自黄病毒科的病毒的NS3蛋白酶的活化，它们还含有细胞穿透片段，并且它们能够抑制或减弱病毒 感染。 本发明还涉及含有这些嵌合肽用于预防和/或治疗由黄病毒科病毒引起的感染的药物化合物。

公开(公告)号：US08410057B2

公开(公告)日：2013-04-02

申请号：US13142471

申请日：2009-12-29

申请人： Ariana Barbera Betancourt ,  Maria del Carmen Dominguez Horta ,  Norailys Lorenzo Perez ,  Gabriel Ramon Padron Palomares ,  Viviana Falcon Cama ,  Ivon Menendez Valdes

发明人： Ariana Barbera Betancourt ,  Maria del Carmen Dominguez Horta ,  Norailys Lorenzo Perez ,  Gabriel Ramon Padron Palomares ,  Viviana Falcon Cama ,  Ivon Menendez Valdes

IPC分类号： A61K38/00 ,  A61K38/16 ,  A61P43/00 ,  A61P3/10 ,  A61P7/12 ,  A61P1/04

CPC分类号： A61K38/1709

摘要： The present invention is related with the field of the medicine, particularly with the use of an APL peptide or its analogues derived from the human heat shock protein of 60 kDa, for the manufacture of a pharmaceutical composition for the treatment of Crohn's disease, ulcerative colitis and diabetes mellitus type 1. This peptide is biodistributed into the gastrointestinal tract and also promotes the induction of apoptosis in activated intestinal lamina propria and peripheral blood T cells of patients with Crohn's disease. Furthermore, this peptide induces apoptosis in mononuclear cells of patients with diabetes mellitus type 1.

摘要翻译： 本发明涉及药物领域，特别是使用衍生自60kDa人热激蛋白的APL肽或其类似物用于制备用于治疗克罗恩病，溃疡性结肠炎的药物组合物 和1型糖尿病。该肽生物分布到胃肠道中，并且还促进克罗恩病患者的活化的肠固定层和外周血T细胞的凋亡诱导。 此外，该肽在1型糖尿病患者的单核细胞中诱导凋亡。